A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Brentuximab vedotin (Primary) ; Ceritinib (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 20 Apr 2018 Planned End Date changed from 1 Apr 2023 to 1 Jul 2023.
- 20 Apr 2018 Planned primary completion date changed from 1 Apr 2023 to 1 Jul 2023.
- 12 Jan 2018 Planned End Date changed from 1 Feb 2023 to 1 Apr 2023.